TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06044623

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CDK 4/6 inhibitors
Description: Either Palbociclib, Ribociclib or Abemaciclib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDK 4/6 inhibitors
Description: Either Palbociclib, Ribociclib or Abemaciclib

Intervention type: DRUG
Group type: OTHER
Intervention: Endocrine therapy
Description: Either Letrozole, Anastrozole, Exemestane or Fulvestrant in combination with CDK 4/6-inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Endocrine therapy
Description: Either Letrozole, Anastrozole, Exemestane or Fulvestrant in combination with CDK 4/6-inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endocrine therapy
Description: Either Letrozole, Anastrozole, Exemestane or Fulvestrant in combination with CDK 4/6-inhibitor
Study: NCT05335174

Intervention type: DEVICE
Intervention: Device: HemoSphere monitor and Acumen IQ sensor.
Description: Patients will be placed on this monitor for the duration of study in the PACU. Followed by 30-day phone call to record cardiovascular complications.
Study: NCT05243017

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: intra-striatal rAAV5-miHTT
Description: One time MRI-guided stereotaxic infusion of rAAV5-miHTT into the brain

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: intra-striatal rAAV5-miHTT
Description: One time MRI-guided stereotaxic infusion of rAAV5-miHTT into the brain

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: intra-striatal rAAV5-miHTT
Description: One time MRI-guided stereotaxic infusion of rAAV5-miHTT into the brain
Study: NCT05209737

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trendelenburg position
Description: A 10-degree head-down position will be used in this group

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Semirecumbent position
Description: A 30-degree head-up position will be used in this group
Study: NCT06276075

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional rehabilitation, the Erigo®Pro table, motor imagery
Description: 66 stroke patients were randomly assigned to three groups (22 people each) with different therapy (conventional, with the addition of Erigo®Pro and enriched with motor imagery). The therapy duration was two weeks. Patients underwent assessment before and after completion of therapy. The study used the Trunk Stability Test, Berg Balance Scale to assess balance, as well as the Riablo device to measure static balance. Additionally, an evaluation of the superficial tension of the transverse abdominis and multifidus muscles was conducted.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional rehabilitation, the Erigo®Pro table, motor imagery
Description: 66 stroke patients were randomly assigned to three groups (22 people each) with different therapy (conventional, with the addition of Erigo®Pro and enriched with motor imagery). The therapy duration was two weeks. Patients underwent assessment before and after completion of therapy. The study used the Trunk Stability Test, Berg Balance Scale to assess balance, as well as the Riablo device to measure static balance. Additionally, an evaluation of the superficial tension of the transverse abdominis and multifidus muscles was conducted.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional rehabilitation, the Erigo®Pro table, motor imagery
Description: 66 stroke patients were randomly assigned to three groups (22 people each) with different therapy (conventional, with the addition of Erigo®Pro and enriched with motor imagery). The therapy duration was two weeks. Patients underwent assessment before and after completion of therapy. The study used the Trunk Stability Test, Berg Balance Scale to assess balance, as well as the Riablo device to measure static balance. Additionally, an evaluation of the superficial tension of the transverse abdominis and multifidus muscles was conducted.
Study: NCT06005831

Intervention type: OTHER
Group type: OTHER
Intervention: sandbag
Description: The standard sandbag used in our clinic, 20 × 20 × 3 cm3 in dimensions and 3 kg in weight
Study: NCT05338450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clemastine Fumarate
Description: 4 mg of Clemastine Fumarate twice daily (8mg/day) orally for 6 months (180 days)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo equivalent to experimental arm
Study: NCT05489458

Intervention type: PROCEDURE
Intervention: Resection
Description: Type A BR-PDAC patients who had a favorable tumor/vascular structures relationship confirmed during surgical exploration underwent resection.

Intervention type: PROCEDURE
Intervention: No Resection
Description: Type A BR-PDAC patients who did not have a favorable tumor/vascular structures relationship confirmed during surgical exploration did not undergo resection.
Study: NCT05730660

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Quercetin group
Description: 2 capsules a day of Quercetin Fitosoma® of 250 mg each

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: 2 tablets per day, white film-coated having the same appearance as Quercetin Fitosoma ® tablets.
Study: NCT05278403

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurological physiotherapy
Description: Application of conventional physical therapy techniques.
Study: NCT06642012

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cash only
Description: Households received 1 mobile cash transfer per month for 6 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cash + Social Behavior Change Communication
Description: Households received 1 mobile cash transfer per month for 6 months but mothers also received an SBCC package that included interpersonal communication (1:1 consultations for mothers), bi-monthly group sessions on key health and nutrition topics, and cooking demonstrations.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cash + top-up cash
Description: Households received 1 mobile cash transfer per month for 6 months, receiving the base cash amount plus an additional cash top-up amount.
Study: NCT06639815

Intervention type: OTHER
Intervention: clinical and radiographic examination
Description: clinical and radiographic examination
Study: NCT05772702

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-loop tACS
Description: Individual alpha tACS
Study: NCT03931005

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collaboration Decision Support Guide
Description: Electronic toolkit intended to help organizational leaders select partners and negotiate partnerships for implementation. This will contain: 1) a brief summary of collaboration approaches associated with implementation, 2) detailed descriptions of collaboration strategies, 3) a decision analysis tool that guides the selection of collaborative strategies given the community context, and 4) sample contract or agreement language that specifies the nature of the partnership and expectations.
Study: NCT04480450

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab is a highly purified, 1328-amino acid antibody with an approximate molecular mass of 145 kD. Rituximab is a mouse human chimeric monoclonal antibody against CD20. Administration leads to between 90 and 100% peripheral B cell depletion via complement dependent cytotoxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab is a highly purified, 1328-amino acid antibody with an approximate molecular mass of 145 kD. Rituximab is a mouse human chimeric monoclonal antibody against CD20. Administration leads to between 90 and 100% peripheral B cell depletion via complement dependent cytotoxicity.
Study: NCT06161649

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: accepting the operation process of automated intelligent education software system
Description: 1. Execute registration and qualification review~2. Automated smart education interaction
Study: NCT06081530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3802876
Description: BI 3802876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3802876
Description: BI 3802876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3802876
Description: BI 3802876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3802876
Description: BI 3802876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3802876
Description: BI 3802876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3802876
Description: BI 3802876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3802876
Description: BI 3802876

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching BI 3802876
Description: Placebo matching BI 3802876

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching BI 3802876
Description: Placebo matching BI 3802876
Study: NCT06396403

Intervention type: OTHER
Intervention: Collection of venous blood samples
Description: collection includes 1 EDTA tube and 1 Sarstedt S-Monovette tube of 5 mL

Intervention type: OTHER
Intervention: Collection of venous blood samples
Description: collection includes 1 EDTA tube and 1 Sarstedt S-Monovette tube of 5 mL

Intervention type: OTHER
Intervention: Collection of venous blood samples
Description: collection includes 1 EDTA tube and 1 Sarstedt S-Monovette tube of 5 mL

Intervention type: OTHER
Intervention: Collection of venous blood samples
Description: collection includes 1 EDTA tube and 1 Sarstedt S-Monovette tube of 5 mL
Study: NCT06078514

Intervention type: PROCEDURE
Intervention: Loop electrosurgical excision procedure (LEEP)
Description: The affected area of cervix is excised under local anesthesia using a small thin electrically charged hardwire loop for simultaneous cutting and electrocoagulation.
Study: NCT04970576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Dose of 20 mg once a day for three months followed by transthoracic echocardiographic assessment for presence/absence of LV thrombus after 4 weeks and 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Dose as per the target INR of 2 to 3 with transthoracic echocardiographic assessment for presence/absence of LV thrombus after 4 weeks and 12 weeks
Study: NCT05698563

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Magnetic resonance imaging
Description: MRI scan with contrast of the foot or feet

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Magnetic resonance imaging
Description: MRI scan with contrast of the foot or feet

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Ultrasound
Description: Ultrasound scan of the feet

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Ultrasound
Description: Ultrasound scan of the feet

Intervention type: DRUG
Group type: OTHER
Intervention: Corticosteroid injection
Description: Administered ultrasound guided to patients with intermetatarsal bursitis

Intervention type: OTHER
Group type: OTHER
Intervention: Clinical foot evaluation
Description: An examination of the feet
Study: NCT06016374

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telerehabilitation
Description: During this study, the patient will be asked to use the TeleRé programme at least 5 times a week for 30 minutes for one month. Through the programme, they will have access to exercises in video format and thus self-rehabilitation as well as serious therapeutic games. The self-education games and videos target the functional and motor recovery of the upper limb. In addition, cognitive functions (attention, memory, etc.) will also be stimulated via the programme. Therapeutic education modules and PROMS assessments will also be available.
Study: NCT05698563

Intervention type: OTHER
Group type: OTHER
Intervention: Picture of the feet
Description: To evaluate the presence of V-sign/spreading toes

Intervention type: OTHER
Group type: OTHER
Intervention: Picture of the feet
Description: To evaluate the presence of V-sign/spreading toes
Study: NCT05018598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration via pressurized metered dose inhaler (pMDI)
Description: CHF5993 pMDI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Administration via pressurized metered dose inhaler (pMDI)
Description: CHF1535 pMDI or CHF5993 pMDI
Study: NCT05635409

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: STEM-PD
Description: STEM-PD is a cryopreserved cell product, consisting of ventral midbrain dopaminergic progenitor cells derived from the clinical-grade hESC line RC17. STEM-PD will be administered using a non-CE marked class III neurosurgical medical device, the Rehncrona-Legradi device, bilaterally in one surgical session to the putamen.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: STEM-PD
Description: STEM-PD is a cryopreserved cell product, consisting of ventral midbrain dopaminergic progenitor cells derived from the clinical-grade hESC line RC17. STEM-PD will be administered using a non-CE marked class III neurosurgical medical device, the Rehncrona-Legradi device, bilaterally in one surgical session to the putamen.
Study: NCT04002063

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT MobileWork-V plus CBT
Description: a smartphone app to assist with CBT homework skills practice plus CBT

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT MobileWork-V plus CBT
Description: a smartphone app to assist with CBT homework skills practice plus CBT

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT alone
Description: CBT therapy individual
Study: NCT05555732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Datopotamab Deruxtecan
Description: Dato-DXd will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Datopotamab Deruxtecan
Description: Dato-DXd will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin will be administered an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be administered an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin will be administered an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.
Study: NCT05756829

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High frequency, low touch virtual health care
Description: Virtual visits between certified diabetes educators and patients occurring every 2 +/- 1 weeks for a total of 6 months
Study: NCT05945355

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pro2 - Low Dose - 40% of participant's MIP
Description: Each participant will be provided a PrO2™ device and trained on its use as well as its accompanying PrO2 Fit™ app. The PrO2™ is a flow-resistive device that provides inspiratory resistance via a fixed 2mm orifice and has Bluetooth connectivity to most IOS/Android devices or Mac/Windows computers. The PrO2™ device and app allows for both 100% adherence monitoring and immediate user biofeedback. Successful IMR repetitions will require that subjects achieve a pressure target that is 40% of their MIP (maximum inspiratory pressure).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pro2 - High Dose - 75% of participant's MIP
Description: Each participant will be provided a PrO2™ device and trained on its use as well as its accompanying PrO2 Fit™ app. The PrO2™ is a flow-resistive device that provides inspiratory resistance via a fixed 2mm orifice and has Bluetooth connectivity to most IOS/Android devices or Mac/Windows computers. The PrO2™ device and app allows for both 100% adherence monitoring and immediate user biofeedback. Successful IMR repetitions will require that subjects achieve a pressure target that is 75% of their MIP (maximum inspiratory pressure).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pro2 - SHAM - 15% of participant's MIP
Description: Each participant will be provided a PrO2™ device and trained on its use as well as its accompanying PrO2 Fit™ app. The PrO2™ is a flow-resistive device that provides inspiratory resistance via a fixed 2mm orifice and has Bluetooth connectivity to most IOS/Android devices or Mac/Windows computers. The PrO2™ device and app allows for both 100% adherence monitoring and immediate user biofeedback. Successful IMR repetitions will require that participants achieve a pressure target that is 15% of their MIP (maximum inspiratory pressure).
Study: NCT06633666

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: 1. Fatigue Principal points: Pishu (BL 20), Ganshu (BL 18), Shenshu (BL 23), Baihui (GV 20), Guanyuan (RN 4), Zusanli (ST 36), Sanyinjiao (SP 6)~2. Anxiety/ depression Principal points: Yintang (EX-HN3), Baihui (GV 20), Taichong (LR 3), Neiguan (PC 6), Danzhong (RN 7)~3. Cognitive impairment/ memory loss Principal points: Baihui (GV 20), Sishencong (EX-HN1), Fengfu (GV 16), Taixi (K 13), Xuanzhong (GB 39), Zusanli (ST 36)~4. Insomnia Principal points: Zhaohai (K 16), Shenmai (BL 62), Shenmen (HT 7), Sanyinjiao (SP 6), Anmian (EX-HN22), Sishencong (EX-HN1)
Study: NCT06169579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ND-003 tablets
Description: ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ND-003 tablets
Description: ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ND-003 tablets
Description: ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ND-003 tablets
Description: ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ND-003 tablets
Description: ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ND-003 tablets
Description: ND-003 tablets will be administered orally and observe 4 days, and followed by over continuous 28-days cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ND-003 tablets
Description: ND-003 tablets will be administered orally over continuous 28-days cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ND-003 tablets
Description: ND-003 tablets will be administered orally over continuous 28-days cycles.
Study: NCT04522375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP-045
Description: activator of aldehyde dehydrogenase
Study: NCT06162312

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antenatal perineal massage
Description: Participants at 34-35 weeks of gestation were received training in self-perineal massage and performed a daily 5-minute massage using water-based jelly until delivery to compare with standard obstetric care on postpartum morbidities
Study: NCT05263791

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airmod
Description: Both of the respiratory rate monitor (including experimental and reference device) are installed on the enrolled patients. The practitioners can clearly read the result of both devices.
Study: NCT06287853

Intervention type: DEVICE
Intervention: Tapestry Biointegrative Implant
Description: The Tapestry RC Biointegrative Implant System is an arthroscopic delivery and fixation system intended for tendon augmentation with Tapestry Biointegrative Implant during arthroscopic rotator cuff (RC) repair. The system combines the biointegrative collagen-based implant (Tapestry Biointegrative Implant) with bioabsorbable fixation ( Bioabsorbable Anchors). Tapestry Biointegrative Implant is a collagen-based implant composed of type I bovine collagen and poly(D,L-lactide). It is designed to function as a non-constricting, protective layer between the tendon and surrounding tissues.

Intervention type: DEVICE
Intervention: Tapestry Biointegrative Implant
Description: The Tapestry RC Biointegrative Implant System is an arthroscopic delivery and fixation system intended for tendon augmentation with Tapestry Biointegrative Implant during arthroscopic rotator cuff (RC) repair. The system combines the biointegrative collagen-based implant (Tapestry Biointegrative Implant) with bioabsorbable fixation ( Bioabsorbable Anchors). Tapestry Biointegrative Implant is a collagen-based implant composed of type I bovine collagen and poly(D,L-lactide). It is designed to function as a non-constricting, protective layer between the tendon and surrounding tissues.
Study: NCT06551961

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: methylcellulose
Description: 2.5 and 5 gm Methylcelllose heated to create a gel

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: inulin
Description: 2.5 and 5 gm inulin powder dissolved in water

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: inulin
Description: 2.5 and 5 gm inulin powder dissolved in water

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: maltodextrin
Description: 2.5 and 5gm maltodextrin dissolved in water
Study: NCT04879563

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ASCAPE-based follow-up strategy
Description: Follow-up through ASCAPE platform including AI-based predictions for health-related QoL issues and suggestions for personalized interventions depending on the type of QoL issue that needs to be tackled.~The ASCAPE-based follow-up strategy includes follow-up through validated QoL questionnaires, wearables for capturing active monitoring data, and mobile apps for answering the questionnaires and capturing potential health-related issues.